NCT03726996View on ClinicalTrials.gov

Desipramine in Infantile Neuroaxonal Dystrophy (INAD).

PHASE4TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions

Infantile Neuroaxonal Dystrophy

Interventions

DRUG

Desipramine

Study drug (desipramine) provided in tablet form to be taken daily.

Trial Locations (1)

27710

Duke University Health Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT03726996 - Desipramine in Infantile Neuroaxonal Dystrophy (INAD). | Biotech Hunter | Biotech Hunter